Safety of Influenza A (H1N1) Vaccine in Postmarketing Surveillance in China
- 17 February 2011
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 364 (7) , 638-647
- https://doi.org/10.1056/nejmoa1008553
Abstract
On September 21, 2009, China began administering vaccines, obtained from 10 different manufacturers, against 2009 pandemic influenza A (H1N1) virus infection in priority populations. We aimed to assess the safety of this vaccination program.Keywords
This publication has 10 references indexed in Scilit:
- Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010Vaccine, 2010
- Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trialThe Lancet, 2010
- A Novel Influenza A (H1N1) Vaccine in Various Age GroupsNew England Journal of Medicine, 2009
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineNew England Journal of Medicine, 2009
- Vaccines and Guillain-Barré SyndromeDrug Safety, 2009
- Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza VaccineJAMA, 2005
- Guillain-Barré Syndrome Following Influenza VaccinationJAMA, 2004
- The Guillain–Barré Syndrome and the 1992–1993 and 1993–1994 Influenza VaccinesNew England Journal of Medicine, 1998
- GUILLAIN-BARRE SYNDROME FOLLOWING VACCINATION IN THE NATIONAL INFLUENZA IMMUNIZATION PROGRAM, UNITED STATES, 1976–19771American Journal of Epidemiology, 1979